US4157400A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Terpenophenoxyalkylamines and pharmaceutical compositions and uses thereof
Assignee: Mar-Pha Sarl d''Etude et d''Exploitation de Marques Ste
•
Filing: 1977-08-08
•
Granted: 1979-06-05
•
Expires: 1997-08-08
Abstract
Abstract 1-ISOPROPYLAMINO-3-[2-(2-NORBORNYL EXO)PHENOXY]PROPAN-2-OL, ITS 1-ISOPROPYLAMINO-3-[2-NORBORNYL ENDO)PHENOXY]PROPAN-2-OL ISOMER AND THEIR ACID ADDITION SALTS AND THEIR QUATERNARY AMMONIUM SALTS. These compounds can be used as beta-blocking agents against disorders of the cardiac rhythm, anti-anxiety and anti-hypertension medicaments.
Inventors
- 👤 Jean Mardiguian
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 04:28
CPC Classifications
C; C07; C07D; C07D303/00; C07D303/02; C07D303/12; C07D303/18; C07D303/20; C07D303/22; A; A61; A61P; A61P25/00; A61P25/02; A61P31/00; A61P31/04; A61P9/00; A61P9/08; A61P9/12
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
26 words
A compound selected from the group consisting of 1-isopropylamino-3-[2-(2-norbornyl exo)phenoxy]propan-2-ol, its isomer: 1-isopropylamino-3-[2-(2-norbornyl endo)phenoxy]propan-2-ol, and physiologically acceptable non-toxic acid addition salts and quaternary ammonium salts thereof.
Claim 2
Dependent Claim
26 words
A compound selected from the group consisting of 1-isopropylamino-3-[2-(2-norbornyl exo)phenoxy]propan-2-ol, its isomer: 1-isopropylamino-3-[2-(2-norbornyl endo)phenoxy]propan-2-ol, and physiologically acceptable non-toxic acid addition salts and quaternary ammonium salts thereof.
Claim 3
Dependent Claim
38 words
A pharmaceutical composition active as a beta-blocking agent against tachycardia, as an anti-anxiety, anti-hypertension and anti-spasmodic medicament which comprises a therapeutically effective amount of at least one compound according to claim 1, and a pharmaceutically acceptable non-toxic carrier.
Claim 4
Independent Claim
59 words
A method for the treatment of tachycardia, of angina pectoris and hypertension which comprises administering orally or intravenously to a patient in need of such treatment a composition containing as the active ingredient a compound which is 1-isopropylamino-3-[2-(2-norbornyl exo)phenoxy]propan-2-ol) or its isomer: 1-isopropylamino-3-[2-(2-norbornyl endo)phenoxy]propan-2-ol to the patient in a daily dose of 20 to 1200 mg. of said compound.
Claim 5
Independent Claim
59 words
A method for the treatment of tachycardia, of angina pectoris and hypertension which comprises administering orally or intravenously to a patient in need of such treatment a composition containing as the active ingredient a compound which is 1-isopropylamino-3-[2-(2-norbornyl exo)phenoxy]propan-2-ol) or its isomer: 1-isopropylamino-3-[2-(2-norbornyl endo)phenoxy]propan-2-ol to the patient in a daily dose of 20 to 1200 mg. of said compound.
Claim 6
Dependent Claim
35 words
Pharmaceutical composition according to claim 2 in the form of a tablet, sugar coated pill, capsule, cachet, suppository, injectable ampoules or drinkable liquid containing between 10 and 200 mg. of said compound per unit dose.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-06-04 | 1982-12-04 | 1983-06-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-06-04 | 1986-12-04 | 1987-06-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-06-04 | 1990-12-04 | 1991-06-05 | $7700.00 | Window Closed / Lapsed |